Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, November 2001, p. 3156-3161, Vol. 45, No. 11
Laboratoire de Microbiologie et Biochimie
Appliquée, ENITA de Bordeaux, 33175 Gradignan
Cedex,1 Laboratoire de
Bactériologie, Université Victor Segalen Bordeaux II, 33076 Bordeaux Cedex,2 Laboratoire de
Génie Enzymatique et Biovalorisation, IUT, 87000 Limoges,3 and Centre de RMN,
Université Claude Bernard, Lyon 1, ESPCPE Lyon, 69622 Villerbanne Cedex,4 France
Received 1 November 2000/Returned for modification 1 March
2001/Accepted 26 July 2001
A limited number of antibiotics can be used against
Helicobacter pylori infection, and resistance jeopardizes
the success of treatment. Therefore, a search for new agents is
warranted. The use of probiotics to enhance gastrointestinal health has
been proposed for many years, but the scientific basis of the
prophylactic and therapeutic actions of probiotics has not yet been
clearly delineated. Probiotic strain Bacillus subtilis 3, whose safety has previously been demonstrated, is known to have
antagonistic properties against species of the family
Enterobacteriaceae. In the present study, it was also found
to inhibit H. pylori. The anti-H. pylori
activity present in the cell-free supernatant was not related to pH or
organic acid concentration. It was heat stable and protease
insensitive. At least two antibiotics, detected by thin-layer
chromatography (Rf values, 0.47 and 0.85, respectively) and confirmed by high-performance liquid chromatographic
analysis, were found to be responsible for this anti-H.
pylori activity. All H. pylori strains tested were
sensitive to both compounds. One of these compounds was identified as
amicoumacin A, an antibiotic with anti-inflammatory properties. MICs
for H. pylori determined in solid and liquid media ranged
between 1.7 and 6.8 µg/ml and 0.75 and 2.5 µg/ml, respectively. The
underestimation of MICs determined in solid medium may be due to
physicochemical instability of the antibiotic under these test
conditions. An additive effect between amicoumacin A and the
nonamicoumacin antibiotic against H. pylori was demonstrated.
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.11.3156-3161.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
In Vitro Anti-Helicobacter pylori
Activity of the Probiotic Strain Bacillus subtilis 3 Is Due
to Secretion of Antibiotics
*
Corresponding author: Mailing address: Laboratoire de
Microbiologie et Biochimie Appliquée, ENITA de Bordeaux, 1, cours
du Général de Gaulle, BP 201, 33175 Gradignan cedex,
France. Phone: 33 5 57 35 59 91. Fax: 33 5 57 35 07 39. E-mail:
m-urdaci{at}enitab.fr.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»